15/05/2026
New research shows major diabetes drug impacts the brain.
For over six decades, metformin has served as the frontline defense against type 2 diabetes, with its success primarily credited to its ability to suppress glucose production in the liver. However, a groundbreaking study from the Baylor College of Medicine has shifted this paradigm, revealing that the drug's efficacy relies heavily on a direct interaction with the brain. Scientists identified that metformin targets the ventromedial hypothalamus, specifically activating specialized neurons to suppress a protein called Rap1. This neural signaling pathway appears essential for the drug’s glucose-lowering effects, marking a significant departure from previous biological understandings that focused almost exclusively on the gut and liver.
This discovery offers more than just a new perspective on diabetes management; it provides a scientific framework for understanding metformin’s broader health benefits, including its potential role in slowing brain aging and promoting longevity. By isolating the Rap1 protein as a critical mediator, researchers believe they have found the key to developing more precise therapies that mimic metformin’s benefits while potentially minimizing common gastrointestinal side effects. As science continues to map the brain’s profound influence on metabolic health, this finding underscores the hidden complexity of a medication relied upon by millions and paves the way for the next generation of precision metabolic treatments.
source: Lin, H.-Y., et al. (2025). Low-dose metformin requires brain Rap1 for its antidiabetic action. Science Advances.
